GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (LTS:0A3M) » Definitions » Price-to-Funds-From-Operations

BioNTech SE (LTS:0A3M) Price-to-Funds-From-Operations : (As of Jun. 09, 2024)


View and export this data going back to 2020. Start your Free Trial

What is BioNTech SE Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


BioNTech SE (LTS:0A3M) Business Description

Industry
Address
An der Goldgrube 12, Mainz, RP, DEU, D-55131
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.